MD Becker Partners' newsletter covering the life science industry
Our management and strategy consulting firm was founded in November 2008, which was clearly a difficult period for the U.S. economy and a year that many investors would like to forget. The Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971. [...]
The life sciences industry [herein includes pharmaceutical, biotechnology, diagnostic and medical device companies] plays a critical role in the United States [US] economy. Innovative new medicines developed by life sciences companies provide better patient outcomes, improved quality of care, increased life expectancy, and lead to economic gains. Currently, the strengths [e.g. innovation, quality of care] [...]
On February 17, 2009, President Obama announced as part of the 2009 stimulus bill, an increase of approximately $10B dollars to the budget for the National Institute of Health (NIH). This is a much needed increase in funding as government sponsored biomedical research has remained relatively flat over the past several years (Figure 1). Whether [...]
As the CEO of a few small, publicly-traded biotechnology companies during the past several years, I find the rationale for determining which companies or industries receive government assistance these days to be a highly confusing subject. Originally it appeared that banks received special attention, until Bear Stearns was deemed too big to fail, while Lehman [...]
Follow MD Becker Partners